东阳光药:自研慢性乙肝siRNA新药国内获批临床

药研界面
Oct 29, 2025

据中国国家药品监督管理局(NMPA)药品审评中心(CDE)公开信息显示,东阳光药siRNA疗法HECN30227慢性乙肝临床试验申请获批准。临床前数据表明,HECN30227具有泛基因型活性,可高效降低HBV表面抗原水平,对核苷类药物耐药株同样保持突出药效,体内外药效亦优于临床竞品。该药物采用东阳光药独特设计的HEC-GalNova(N-乙酰半乳糖胺)肝靶向递送系统,在实现精准高效肝脏递送的同时...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10